Pharmaceutical Sector

Cadila Healthcare Q4 net rises 11.62%; announces dividend of Rs 4.50 per share

Cadila Healthcare Q4 net rises 11.62%; announces dividend of Rs 4.50 per shareCadila Healthcare Ltd, on Tuesday announced an increase of 11.62% in its net profit at Rs 58 crore for the second quarter ended March 31, 2009, compared to Rs 51.96 crore in the year-ago period.

Further, total income of the company for the quarter also rose 29.25% to Rs 727.73 crore, compared to Rs 563 crore for prior year period.

For the full-year ended March, Cadila Healthcare’s net profit surged 17.65% to Rs 303.08 crore, as compared to Rs 257.59 crore for the year ended March 31, 2008.

Pfizers profit, earnings, drop despite Viagra boom

Pfizers profit, earnings, drop despite Viagra boom Washington - Pfizer Inc, the worlds biggest drugmaker, Tuesday said profits were down 2 per cent and revenues were down 8.3 per cent compared to first quarter 2008 despite blockbuster drugs like the impotence pill Viagra and cholesterol-busting Lipitor. Net income dropped to 2.73 billion dollars, while revenues were down to 10.9 billion dollars, the company said.

Profits were eroded by the rising dollar, which lowered income from abroad, the company said.

Biocon Q4 net profit plunges 61%

BioconBiocon Ltd, a fully integrated healthcare company that delivers innovative biopharmaceutical solutions, has registered 61% decline its net profit to Rs 24.14 crore for the fourth quarter ended March 31, 2009, against Rs 62.03 crore reported during the same quarter ended March 31, 2008.

In addition, company's total income for the quarter has also increased to Rs 239.84 crore from Rs 236.71 crore during the same quarter in 2007-08.

For the financial year ended March 2009, the company posted a net profit after tax of Rs 111.81 crore, down 74 per cent against Rs 434.94 crore in FY'08.

Swiss flu medicine company sees stock rise with outbreak

Swiss flu medicine company sees stock rise with outbreakGeneva - The Swiss pharmaceutical giant Roche, maker of influenza medication Tamiflu, saw its stock price rise 3.6 per cent in trading late Monday afternoon on the Zurich exchange on the back of the global swine flu outbreak. During the avian flu epidemic the drug was used heavily, particularly in South Asia.

Shares in Roche were trading at close to 145 Swiss francs (126 dollars), up over five francs since the opening.

Cipla Q4 net profit soars 41%

Cipla Q4 net profit soars 41%Leading drug maker Cipla on Friday reported 40.94% surge in its net profit for the fourth quarter ended March 31.

The company posted net profit of Rs 252.92 crore, against Rs 179.45 crore in the same quarter ended March 31, 2008.

Further, during the quarter, total operating income of the company rose to Rs 1,366.74 crore, as against Rs 1,122.10 crore in the same quarter of the previous fiscal.

For the full-year ended March, the company posted a net profit of Rs 767 crore, as compared to Rs 701 crore in the corresponding period last year

NYSE-listed Covidien to enter Indian Healthcare Market

NYSE-listed Covidien to enter Indian Healthcare Market Covidien, a $10 billion global healthcare products leader, has announced its entry into the Indian healthcare market with the establishment of its headquarters at Gurgaon.

The company intends to collaborate with the region's healthcare providers to offer its cutting-edge medical solutions and services throughout the country.

According to sources, Covidien will setup three 'dry labs' this year to initiate training programmes for medical practitioners in the country. In addition, it will also introduce some of its patented products in India.

Pages